Competition for Early-Line Biologic Use among Psoriasis Patients Intensifies as Humira Continues to Gain Ground on Enbrel

Humira Leads Remicade in the Treatment Algorithm for Psoriatic Arthritis Despite Launching Around the Same Time, According to New Analysis from Decision Resources

BURLINGTON, Mass.--(BUSINESS WIRE)-- Decision Resources, one of the world’s leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that competition for early-line use of Amgen/Pfizer’s Enbrel and Abbott’s Humira continues to intensify in the treatment of psoriasis. According to new analysis of U.S. patient-level claims data, while Enbrel remains the most commonly used biologic in the treatment of psoriasis, Humira continues to see sustained quarter-over-quarter uptake among recently treated psoriasis patients, while Enbrel’s patient share has experienced a decline.

“Although Humira was the last tumor necrosis factor-alpha (TNF-alpha) inhibitor to be approved for psoriasis in the United States, it is quickly gaining market share,” said Decision Resources Analyst Iva Holder, Ph.D. “Humira is increasingly prescribed for patients requiring or preferring efficacy greater than that of Enbrel. Thus, its increasing patient share is largely due to patients’ and physicians’ growing preference for Humira.”

Humira has also made inroads in the psoriatic arthritis market, where it has secured an advantage over Janssen Biotech’s Remicade for earlier positioning in the psoriatic arthritis treatment algorithm, despite launching around the same time. Recent analysis finds that at all three lines of therapy, Remicade’s patient share trails that of both Enbrel and Humira.

“Remicade has superior efficacy in treating psoriatic lesions compared with other marketed TNF-alpha inhibitors,” said Decision Resources Analyst Dancella Fernandes, Ph.D., M.B.A. “Yet, its intravenous administration and perceived safety disadvantages have limited its uptake.”

The analysis is part of Decision Resources’ Treatment Algorithms series. Through examination of patient-level claims data, the Treatment Algorithms series provides exceptional insight into physicians’ prescribing trends and the factors that drive therapy choice, from diagnosis through multiple courses of treatment, for a specific disease. The Treatment Algorithms series is updated quarterly.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.



CONTACT:

Decision Resources
Lisa Osgood, 781-993-2606
[email protected]
or
Decision Resources Group
Christopher Comfort, 781-993-2597
[email protected]

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Pharmaceutical  Research  Science  General Health

MEDIA:

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.